{
    "clinical_study": {
        "@rank": "109335", 
        "arm_group": [
            {
                "arm_group_label": "Placebo (for QLT091001)", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo is supplied to mimic QLT091001 oral solution."
            }, 
            {
                "arm_group_label": "QLT091001 - first oral dose", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will receive an oral dose of 10mg/m2 of QLT091001."
            }, 
            {
                "arm_group_label": "QLT091001  - second oral dose", 
                "arm_group_type": "Experimental", 
                "description": "Subjects will receive an oral dose of 40 mg/m2 of QLT091001."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a Phase IIa proof-of-concept study to evaluate the effects of oral QLT091001 on\n      adults with impaired dark adaptation."
        }, 
        "brief_title": "Evaluation of the Effects of Oral QLT091001 in Adults With Impaired Dark Adaptation", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Impaired Dark Adaptation", 
        "detailed_description": {
            "textblock": "This proof-of-concept study is a randomized, parallel design of two different oral doses of\n      QLT091001 compared to placebo to evaluate treatment effects in patients with impaired dark\n      adaptation.\n\n      Approximately 40 subjects will be enrolled in this study at approximately 7 centers in the\n      US."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female subjects \u226560 yrs with early age-related macular degeneration (AMD)\n             based on LLLC BCVA criterion or evidence of impaired dark adaptation\n\n          -  Subjects with high luminance high contrast best-corrected visual acuity (HLHC BCVA)\n             of 40 letters (20/40 Snellen) or better in the study eye\n\n          -  Capable and willing to provide consent\n\n        Exclusion Criteria:\n\n          -  Women of child bearing potential\n\n          -  Subjects with late AMD or any other optic neuropathy in the study eye\n\n          -  Subjects with posterior subcapsular cataract or multifocal intra-ocular lens (IOL) in\n             the study eye\n\n          -  Subjects who are actively participating in an experimental therapy study or who have\n             received experimental therapy within 60 days of Day 0 or who have taken any\n             prescription/investigational oral retinoid medication within 6 months of Day 0\n\n          -  Subjects taking age-related eye disease study (AREDS) supplements containing\n             beta-carotene"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "60 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01999764", 
            "org_study_id": "RET IDA 02"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "QLT091001 - first oral dose", 
                    "QLT091001  - second oral dose"
                ], 
                "description": "QLT091001 administered orally at multiple time points.", 
                "intervention_name": "QLT091001", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo (for QLT091001)", 
                "description": "Placebo is administered orally at multiple time points.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 15, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Artesia", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90701"
                    }, 
                    "name": "Sall Research Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Santa Barbara", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "93103"
                    }, 
                    "name": "California Retina Consultants"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02114"
                    }, 
                    "name": "Ophthalmic Consultants of Boston"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Austin", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78731"
                    }, 
                    "name": "Keystone Research Ltd."
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Dallas", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "75231"
                    }, 
                    "name": "Retina Foundation of the Southwest"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "77030"
                    }, 
                    "name": "Retina Consultants of Houston"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Seattle", 
                        "country": "United States", 
                        "state": "Washington", 
                        "zip": "98004"
                    }, 
                    "name": "Proliance Surgeons Inc."
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "Evaluation of the Effects of Oral QLT091001 in Adults With Impaired Dark Adaptation", 
        "other_outcome": {
            "description": "Glare recovery time will be measured at multiple time points.", 
            "measure": "Glare Recovery", 
            "safety_issue": "No", 
            "time_frame": "Through 7 weeks"
        }, 
        "overall_official": {
            "affiliation": "QLT Inc.", 
            "last_name": "Sushanta Mallick, Ph.D MBA", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Low luminance low contrast best-corrected visual acuity (LLLC BCVA) will be measured at multiple time points.", 
            "measure": "Visual Acuity", 
            "safety_issue": "No", 
            "time_frame": "Through 7 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01999764"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Dark Adaptation Time will be measured at multiple time points.", 
            "measure": "Dark Adaptation Time", 
            "safety_issue": "No", 
            "time_frame": "Through 7 weeks"
        }, 
        "source": "QLT Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "QLT Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}